Biomedicines Webinar | Emerging Trends in Pathophysiology and Therapy of COVID-19
Biomedicines Webinar | Emerging Trends in Pathophysiology and Therapy of COVID-19
Part of the MDPI Biomedicines Webinars series
COVID-19, SARS-CoV-2, Viral infections
Welcome from the Chair
14th Biomedicines Webinar
Emerging Trends in Pathophysiology and Therapy of COVID-19
I am pleased to serve as the Chairman of this webinar on Emerging Trends in Pathophysiology and Therapy of COVID-19.
Although the worst of the SARS CoV-2 pandemic is behind us, many questions and issues persist. Systemic manifestations due to COVID-19 infections and long COVID continue to emerge in multiple countries. There are a few new USA FDA-approved vaccines available in addition to the Moderna, Pfizer, and Johnson and Johnson ones, but vaccine effectiveness and immunologic memory appear to be limited in most patients.
Therapies are available and should be incorporated into treatment plans for COVID-19 patients. Although the focus of these therapies is on hospitalized COVID-19 patients, orally delivered medications are now administered by health care providers.
This webinar will present discussions on these issues, as well as emerging trends, to understand COVID-19 infections and transmissibility more fully.
Date: 4 June 2024 at 5:00 CEST | 11:00 a.m. EDT | 11:00 p.m. CST AsiaWebinar ID: 828 4947 7200
Webinar Secretariat: journal.webinar@mdpi.com
Event Chair
University of Maryland,
University of Washington,
Nova Southeastern University,
Temple University
Periodontal Disease Implications for COVID-19 Infections
Prof. Dr. Jon Suzuki holds Clinical Professorships at the University of Maryland, the University of Washington, and Nova Southeastern University. He is Professor Emeritus of Microbiology and Immunology (School of Medicine) and Professor Emeritus of Periodontology and Oral Implantology (School of Dentistry) at Temple University, Philadelphia, PA., USA. He is also a Special Government Agent for the Food and Drug Administration (FDA) Dental Products Advisory Panel. Dr. Suzuki received his D.D.S. from Loyola University of Chicago and his Ph.D. in Microbiology from the Illinois Institute of Technology. He completed an N.I.H. Fellowship in Immunology at the University of Washington, and a Clinical Certificate in Periodontics at the University of Maryland.
jsuzuki@temple.edu
Webinar Recording
Keynote Speakers
University of Maryland, USA,
University of Washington, USA,
Nova Southeastern University, USA,
Temple University, USA
Periodontal Disease Implications for COVID-19 Infections
Prof. Dr. Jon Suzuki holds Clinical Professorships at the University of Maryland, the University of Washington, and Nova Southeastern University. He is Professor Emeritus of Microbiology and Immunology (School of Medicine) and Professor Emeritus of Periodontology and Oral Implantology (School of Dentistry) at Temple University, Philadelphia, PA., USA. He is also a Special Government Agent for the Food and Drug Administration (FDA) Dental Products Advisory Panel. Dr. Suzuki received his D.D.S. from Loyola University of Chicago and his Ph.D. in Microbiology from the Illinois Institute of Technology. He completed an N.I.H. Fellowship in Immunology at the University of Washington, and a Clinical Certificate in Periodontics at the University of Maryland.
jsuzuki@temple.edu
Emerging Trends in Post-COVID-19 therapy
Dr. Sorrentino's research focuses on the understanding and analysis of inflammation pathways and immune cells involved in acute and chronic lung pathologies.
rsorrentino@unisa.it
Department of Medicine, Surgery and Health Sciences, University of Trieste, Italy
COVID-19: From Pathophysiology to Therapy: The Leading Role of Autopsy 4 Years After The Lockdown of Science
Active in the fields of forensic pathology and toxicology, bioethics and clinical risk management, and medical liability. Research interests include forensic autopsy technique, forensic pathology, forensic toxicology, cardiopathology, sudden death, and clinical risk management. Expert witness for the Italian Courts. Manager of the Registry of Sudden Cardiac Death in Friuli-Venezia Giulia, Italy.
sderrico@units.it
Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy
Biological Markers for Pulmonary Fibrosis Sequelae Post-COVID-19
Dr. D'Alessandro started her research in translational medicine for lung diseases with the project "Interaction between solid lipid nanoparticles and respiratory epithelial cells: in vitro study of uptake and biocompatibility". Since then, D'Alessandro has researched novel biomarkers of diffuse lung diseases, asthma, COVID-19, and lung transplantation. Her research focuses on the immune system in different biological matrices - including bronchoalveolar lavage of fibrotic interstitial lung disease patients and the validation of novel biomarkers such as the Krebs von den Lungen-6 and extracellular vesicles.
dalessandro.miriana@gmail.com
Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy
Biological Markers for Pulmonary Fibrosis Sequelae Post-COVID-19
Dr. Gangi is a PhD candidate in the Respiratory Diseases Unit at the University of Siena. Her project focuses on the analysis of prognostic and diagnostic biomarkers in fibrotic interstitial lung diseases, COVID-19, and lung transplants. Dr. Gangi has developed a good knowledge base on cell culture, flow cytometry analysis, and chemiluminescent methods. She worked on the development of a novel fibroblast cell line isolated by bronchoalveolar lavage of IPF patients. She has authored/coauthored 17 research documents and given lectures at national/international congresses.
sara.gangi@student.unisi.it
Registration
After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations with academic or institutional email addresses will be prioritized.
Unable to attend? Feel free to still register, we’ll let you know when the recording is available to watch.
Program
| Speaker/Presentation | Time in CEST |
|
Prof. Dr. Jon Suzuki |
5:00–5:30 pm |
| Dr. Rosalinda Sorrentino Emerging Trends in Post-COVID-19 Therapy |
5:30–5:50 pm |
| Prof. Dr. Stefano D'Errico COVID-19: From Pathophysiology to Therapy: The Leading Role of Autopsy 4 Years After The «Lockdown of Science» |
5:50–6:10 pm |
| Dr. Mariana D’Alessandro Biological Markers for Pulmonary Fibrosis Sequelae Post-COVID-19 (Part 1) |
6:10–6:20 pm |
| Dr. Sara Gangi Biological Markers for Pulmonary Fibrosis Sequelae Post-COVID-19 (Part 2) |
6:20–6:30 pm |
| Q&A | 6:30–6:45 pm |
| Prof. Dr. Jon Suzuki Closing of Webinar |
6:45–6:50 pm |
Relevant Special Issue
Emerging Trends in Pathophysiology and Therapy of COVID-19
Guest Editors: Dr. Jon B. Suzuki, Dr. Miriam Ting
Deadline for manuscript submissions: 31 October 2024
Sponsors and Partners
Organizers
